Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

/a>

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive NHL, that the substitution of pixantrone for doxorubicin in the CHOP regimen may not produces complete remissions and long-term disease free survival in patients with relapsed or refractory, aggressive NHL who previously failed frontline CHOP therapy, that there may not be a correlation between CR/CRu's and progression free survival, that pixantrone may not show an overall improvement rate in survival for patients independent of factors known to influence survival, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials or the total number of patients enrolled, that CTI cannot predict whether PIX-R will serve as either a post-marketing commitment trial or as a pivotal trial, that CTI cannot predict the outcome of the formal dispute resolution process with the FDA, that the FDA may not make its decision on the appeal in the second quarter of 2011, that the FDA may request additional clinical trials, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Publicis Groupe customer engagement agency ... and Healthcare Industry Group Leader, has been featured in ... most inspiring people in the life-sciences industry. Those chosen ... development, marketing, technology, creativity, strategy and medicine. ... partner in its leading Rosetta Consulting practice. In 2012, ...
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- ScriptPro has been ... under its Common Security Framework (CSF). According to ... Privacy Manager, "We appreciate this rigorous, top-to-bottom audit. ... that this certification signifies. Our business partners need ... THE CSF CERTIFICATION PROCESS: ScriptPro,s internal security processes ...
Breaking Medicine Technology:Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2
(Date:8/22/2014)... (PRWEB) August 22, 2014 Millennium Treatment Group ... resulting in a high level of drug use among teenagers. ... fight against drug addiction and work to minimize drug abuse. ... of alcohol and drug addiction in history. According to the ... estimated 23.9 million Americans aged 12 or older—or 9.2 percent ...
(Date:8/22/2014)... The regional economy is about to get a ... grow again. The plant will invest $100 million ... production of the popular Highlander midsize sport utility vehicle. ... $4 billion. This step allows Toyota to utilize existing ... adjust its product mix to meet changing customer demand. ...
(Date:8/22/2014)... A Penn Medicine team has found that targeted ... urinary tract infections in hospital patients with urinary ... alert was simplified, the rate of improvement dramatically ... their patients need urinary catheters in the first ... need for catheters that have not been removed ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Many Americans know little ... the possibility of an outbreak in the United States, a ... they are worried that there will be a major Ebola ... they or an immediate family member will get sick with ... latest Harvard School of Public Health poll. However, those ...
(Date:8/22/2014)... Millennium Treatment Group, a drug ... recently launched a new website. Patients, parents, loved ... now find Millennium Treatment Group at http://www.millenniumtreatmentgroup.com ... at the beginning of July. Everything anyone would ... found on the website. There’s an About Us ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 3Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Millennium Treatment Group Has a New Website 2
... no hard and fast rule as to how a mother should ... than glad to endorse that view as standard positions like sitting ... to override. , Take the case of Nicola Adolphe. ... daughter Deborah was born. ,As manager of a play ...
... had enough. Most Doctors are on the brink of burn ... survey conducted by the Australian Medical Association has found that ... staff shortage, outdated equipments and under trained colleagues from abroad. ... have closed down due to the shortage of doctors. The ...
... a checklist for doctors and nurse to avoid common errors ... hands by the health workers help spread disease to ... to improve patient safety around the world and lessen the ... safety is a primary concern in both developed and developing ...
... clearly raise the risk of the allergic sensitisation of children ... , however, the influence of the environment at home on ... the conclusion reached by scientists from the GSF National ... ,The study published by Chih-Mei Chen et al. in ...
... calcium and vitamin D are significantly more likely to have ... can increase risk of cognitive impairment, dementia, depression and stroke. ... and the University of North Carolina examined magnetic resonance imaging ... women) between the ages of 60 and 86 (average age ...
... of maternity units in UK is an eye-opener to prevailing ... the hospitals. In a sting operation conducted by BBC, some ... practices. ,Some of the maternity units were facing ... were overburdened with work. The midwife in charge at a ...
Cached Medicine News:Health News:New Research Promises To Take The Pain Off Breast Feeding 2Health News:New Research Promises To Take The Pain Off Breast Feeding 3Health News:UN Agencys Checklist on Health Care Error 2Health News:Cats at Home Poses Allergy Risk in Young Children 2Health News:Higher Intake of Calcium and Vitamin D Linked With Brain Lesions in Older People 2Health News:United Kingdom: Maternity Units Exposed! Leaves Much to Be Desired 2
... Developed to be used in facilities where ... the latest ventilation and gas delivery technologies ... the ability and the functionality of the ... to create yourself a workplace environment that ...
... The Aestiva/5 Pendant anesthesia machine offers ... patient range with the SmartVent ventilator. ... than superior ventilation. Enhancements in flexibility, ... evolution in anesthesia delivery., ,The ...
... The S/5 Avance Carestation was developed ... solutions close and continuous collaboration ... the compact, integrated anesthesia carestation that ... best in anesthesia patient monitoring, and ...
The Electronic bag and bottle ventilator especially designed for your circle system needs. Provides the anaesthetist with a wide range of economic anaesthesia solutions with the following outstanding...
Medicine Products: